INABHealthcare · BiotechnologyINAB Stock Forecast: IN8bio, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering IN8bio, Inc. hold a median 12-month price target of $5.5 — +333.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.
INAB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores IN8bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Value (8): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
INAB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +333.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $6.00 |
| 14 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2025 | Jones Trading | Upgrade | Buy | — |
| 26 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 12 Aug 2024 | Jones Trading | Downgrade | Hold | — |
| 14 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 June 2024 | Jones Trading | Maintains | Buy | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2024 | Laidlaw & Co. | Initiates | Buy | — |
| 15 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2024 | JonesTrading | Initiates | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 June 2023 | EF Hutton | Reiterates | Buy | — |
| 16 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INAB appears on the weeks it earns a place.
INAB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
IN8bio, Inc. (INAB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.3×
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- 0.2×
Cheaper than 79% of US stocks
Cheaper than 82% of US stocks
Cheaper than 60% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −111.1%
- Return on assets
- −58.4%
- Dividend yield
- —
Higher than 12% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
INAB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own IN8bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about INAB stock
What is the INAB stock price forecast for 2026-2027?
The 4 Wall Street analysts covering IN8bio, Inc. have a median 12-month price target of $5.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is INAB stock a buy right now?
Of the 4 analysts covering IN8bio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IN8bio, Inc. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INAB?
As at 22 Aug 2026, IN8bio, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
Will INAB stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +333.1% from the last close, and Ticker Nerd's factor model ranks IN8bio, Inc. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the INAB stock forecast for 2030?
No analyst covering IN8bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
How has INAB stock performed over the past year?
IN8bio, Inc. returned -43.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does IN8bio, Inc. do?
IN8bio Inc. is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of gamma-delta T cell therapies aimed at treating cancer.
About IN8bio, Inc.
IN8bio Inc. is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of gamma-delta T cell therapies aimed at treating cancer. Leveraging its proprietary DeltEx™ platform, the company develops innovative cell therapies employing various approaches, including allogeneic, autologous, induced pluripotent stem cell (iPSC), and genetically modified gamma-delta T cells. These specialized immune cells have unique capabilities to distinguish healthy from diseased tissue, functioning as a bridge between innate and adaptive immunity with potent antitumor activity. IN8bio’s lead candidates include INB-400 and INB-200, in clinical trials targeting glioblastoma, and INB-100, aimed at hematologic malignancies in patients undergoing bone marrow transplantation. Beyond these, its pipeline encompasses multiple preclinical and discovery-stage programs focused on solid and hematological tumors, reflecting its commitment to advancing next-generation cellular immunotherapies and striving toward the elimination of cancer.
CEO Mr. Tai-Wei Ho · 18 employees · United States · https://in8bio.com